Insulin like growth factor-1 prevents 1-mentyl-4-phenylphyridinium-induced apoptosis in PC12 cells through activation of glycogen synthase kinase-3beta

Toxicology

Volumn 271, Issue 1-2, 2010, Pages 5-12

  Sun, Xin ^a   Huang, Luqi ^b   Zhang, Min ^b   Sun, Shenggang ^b   Wu, Yan ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

ERK1 2; GSK 3beta; IGF 1; MPP+; Parkinson's disease

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; ACRIDINE ORANGE; ETHIDIUM BROMIDE; GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM CHLORIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RECOMBINANT SOMATOMEDIN C;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL PROTECTION; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PHEOCHROMOCYTOMA CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL SURVIVAL; CHROMONES; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLAVONOIDS; GLYCOGEN SYNTHASE KINASE 3; INSULIN-LIKE GROWTH FACTOR I; LITHIUM CHLORIDE; MORPHOLINES; NEUROTOXINS; PARKINSON DISEASE; PC12 CELLS; PROTEIN KINASE INHIBITORS; RATS; RECOMBINANT PROTEINS;

EID: 77951296766     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2010.01.001     Document Type: Article

References (42)

1. Beal M.F. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment. J. Bioenerg. Biomembr. 2004, 36:381-386.
2. Bhat R.V., Shanley J., Correll M.P., Fieles W.E., Keith R.A., Scott C.W., Lee C.M. Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:11074-11079.
3. Bibollet-Bahena O., Almazan G. IGF-1-stimulated protein synthesis in oligodendrocyte progenitors requires PI3K/mTOR/Akt and MEK/ERK pathways. J. Neurochem. 2009, 109:1440-1451.
4. Burgos-Ramos E., Martos-Moreno G.A., Lopez M.G., Herranz R., Aguado-Llera D., Egea J., Frechilla D., Cenarruzabeitia E., Leon R., Arilla-Ferreiro E., Argente J., Barrios V. The N-terminal tripeptide of insulin-like growth factor-I protects against beta-amyloid-induced somatostatin depletion by calcium and glycogen synthase kinase 3 beta modulation. J. Neurochem. 2009, 109:360-370.
5. Cappelletti G., Maggioni M.G., Maci R. Influence of MPP+ on the state of tubulin polymerisation in NGF-differentiated PC12 cells. J. Neurosci. Res. 1999, 56:28-35.
6. Chalimoniuk M., Stolecka A., Zieminska E., Stepien A., Langfort J., Strosznajder J.B. Involvement of multiple protein kinases in cPLA phosphorylation, arachidonic acid release, and cell death in in vivo and in vitro models of 1-methyl-4-phenylpyridinium-induced parkinsonism-the possible key role of PKG. J. Neurochem. 2009.
7. Cross D.A., Alessi D.R., Cohen P., Andjelkovich M., Hemmings B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995, 378:785-789.
8. Davila D., Piriz J., Trejo J.L., Nunez A., Torres-Aleman I. Insulin and insulin-like growth factor I signalling in neurons. Front. Biosci. 2007, 12:3194-3202.
9. de Rijk M.C., Launer L.J., Berger K., Breteler M.M., Dartigues J.F., Baldereschi M., Fratiglioni L., Lobo A., Martinez-Lage J., Trenkwalder C., Hofman A. Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000, 54:S21-S23.
10. Di Segni A., Farin K., Pinkas-Kramarski R. ErbB4 activation inhibits MPP+-induced cell death in PC12-ErbB4 cells: involvement of PI3K and Erk signaling. J. Mol. Neurosci. 2006, 29:257-267.
11. Dore S., Kar S., Quirion R. Insulin-like growth factor I protects and rescues hippocampal neurons against beta-amyloid- and human amylin-induced toxicity. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:4772-4777.
12. Forno L.S. Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 1996, 55:259-272.
13. Gelinas S., Martinoli M.G. Neuroprotective effect of estradiol and phytoestrogens on MPP+-induced cytotoxicity in neuronal PC12 cells. J. Neurosci. Res. 2002, 70:90-96.
14. Goto M., Iwase A., Harata T., Takigawa S., Suzuki K., Manabe S., Kikkawa F. IGF1-induced AKT phosphorylation and cell proliferation are suppressed with the increase in PTEN during luteinization in human granulosa cells. Reproduction 2009, 137:835-842.
15. Hajduch E., Alessi D.R., Hemmings B.A., Hundal H.S. Constitutive activation of protein kinase B alpha by membrane targeting promotes glucose and system A amino acid transport, protein synthesis, and inactivation of glycogen synthase kinase 3 in L6 muscle cells. Diabetes 1998, 47:1006-1013.
16. Hallett P.J., Standaert D.G. Rationale for and use of NMDA receptor antagonists in Parkinson's disease. Pharmacol. Ther. 2004, 102:155-174.
17. Hatanaka H. Nerve growth factor-mediated stimulation of tyrosine hydroxylase activity in a clonal rat pheochromocytoma cell line. Brain Res. 1981, 222:225-233.
18. Hong F., Kwon S.J., Jhun B.S., Kim S.S., Ha J., Kim S.J., Sohn N.W., Kang C., Kang I. Insulin-like growth factor-1 protects H9c2 cardiac myoblasts from oxidative stress-induced apoptosis via phosphatidylinositol 3-kinase and extracellular signal-regulated kinase pathways. Life Sci. 2001, 68:1095-1105.
19. Infanger M., Faramarzi S., Grosse J., Kurth E., Ulbrich C., Bauer J., Wehland M., Kreutz R., Kossmehl P., Paul M., Grimm D. Expression of vascular endothelial growth factor and receptor tyrosine kinases in cardiac ischemia/reperfusion injury. Cardiovasc. Pathol. 2007, 16:291-299.
20. Itano Y., Kitamura Y., Nomura Y. 1-Methyl-4-phenylpyridinium (MPP+)-induced cell death in PC12 cells: inhibitory effects of several drugs. Neurochem. Int. 1994, 25:419-424.
21. Kao S.Y. Rescue of alpha-synuclein cytotoxicity by insulin-like growth factors. Biochem. Biophys. Res. Commun. 2009, 385:434-438.
22. Krishna M., Narang H. The complexity of mitogen-activated protein kinases (MAPKs) made simple. Cell. Mol. Life Sci. 2008, 65:3525-3544.
23. Lewis T.S., Shapiro P.S., Ahn N.G. Signal transduction through MAP kinase cascades. Adv. Cancer Res. 1998, 74:49-139.
24. Mairet-Coello G., Tury A., DiCicco-Bloom E. Insulin-like growth factor-1 promotes G(1)/S cell cycle progression through bidirectional regulation of cyclins and cyclin-dependent kinase inhibitors via the phosphatidylinositol 3-kinase/Akt pathway in developing rat cerebral cortex. J. Neurosci. 2009, 29:775-788.
25. Mizuno Y., Hattori N., Matsumine H. Neurochemical and neurogenetic correlates of Parkinson's disease. J. Neurochem. 1998, 71:893-902.
26. Mutoh T., Tokuda A., Marini A.M., Fujiki N. 1-Methyl-4-phenylpyridinum kills differentiated PC12 cells with a concomitant change in protein phosphorylation. Brain Res. 1994, 661:51-55.
27. Offen D., Shtaif B., Hadad D., Weizman A., Melamed E., Gil-Ad I. Protective effect of insulin-like-growth-factor-1 against dopamine-induced neurotoxicity in human and rodent neuronal cultures: possible implications for Parkinson's disease. Neurosci. Lett. 2001, 316:129-132.
28. Pap M., Cooper G.M. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway. J. Biol. Chem. 1998, 273:19929-19932.
29. Peterson A.L., Nutt J.G. Treatment of Parkinson's disease with trophic factors. Neurotherapeutics 2008, 5:270-280.
30. Rebois R.V., Reynolds E.E., Toll L., Howard B.D. Storage of dopamine and acetylcholine in granules of PC12, a clonal pheochromocytoma cell line. Biochemistry 1980, 19:1240-1248.
31. Satoh S., Yanagita T., Maruta T., Nemoto T., Yoshikawa N., Kobayashi H., Tono T., Wada A. Proteasomal degradation of IRS-2, but not IRS-1 by calcineurin inhibition: attenuation of insulin-like growth factor-I-induced GSK-3beta and ERK pathways in adrenal chromaffin cells. Neuropharmacology 2008, 55:71-79.
32. Shaw M., Cohen P., Alessi D.R. Further evidence that the inhibition of glycogen synthase kinase-3beta by IGF-1 is mediated by PDK1/PKB-induced phosphorylation of Ser-9 and not by dephosphorylation of Tyr-216. FEBS Lett. 1997, 416:307-311.
33. Singh N., Pillay V., Choonara Y.E. Advances in the treatment of Parkinson's disease. Prog. Neurobiol. 2007, 81:29-44.
34. Tuler S.M., Hazen A.A., Bowen J.M. Release and metabolism of dopamine in a clonal line of pheochromocytoma (PC12) cells exposed to fenthion. Fundam. Appl. Toxicol. 1989, 13:484-492.
35. Wine R.N., McPherson C.A., Harry G.J. IGF-1 and pAKT signaling promote hippocampal CA1 neuronal survival following injury to dentate granule cells. Neurotox. Res. 2009.
36. Wruck C.J., Claussen M., Fuhrmann G., Romer L., Schulz A., Pufe T., Waetzig V., Peipp M., Herdegen T., Gotz M.E. Luteolin protects rat PC12 and C6 cells against MPP+ induced toxicity via an ERK dependent Keap1-Nrf2-ARE pathway. J. Neural Transm. Suppl. 2007, 57-67.
37. Yan C.Y., Greene L.A. Prevention of PC12 cell death by N-acetylcysteine requires activation of the Ras pathway. J. Neurosci. 1998, 18:4042-4049.
38. Yin Q.W., Johnson J., Prevette D., Oppenheim R.W. Cell death of spinal motoneurons in the chick embryo following deafferentation: rescue effects of tissue extracts, soluble proteins, and neurotrophic agents. J. Neurosci. 1994, 14:7629-7640.
39. Youdim M.B., Arraf Z. Prevention of MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) dopaminergic neurotoxicity in mice by chronic lithium: involvements of Bcl-2 and Bax. Neuropharmacology 2004, 46:1130-1140.
40. Zheng W.H., Kar S., Quirion R. Insulin-like growth factor-1-induced phosphorylation of the forkhead family transcription factor FKHRL1 is mediated by Akt kinase in PC12 cells. J. Biol. Chem. 2000, 275:39152-39158.
41. Zheng W.H., Kar S., Quirion R. Insulin-like growth factor-1-induced phosphorylation of transcription factor FKHRL1 is mediated by phosphatidylinositol 3-kinase/Akt kinase and role of this pathway in insulin-like growth factor-1-induced survival of cultured hippocampal neurons. Mol. Pharmacol. 2002, 62:225-233.
42. Zhong J., Zhao L., Du Y., Wei G., Yao W.G., Lee W.H. Delayed IGF-1 treatment reduced long-term hypoxia-ischemia-induced brain damage and improved behavior recovery of immature rats. Neurol. Res. 2009, 31:483-489.